

Surviving Sepsis Campaign®

SURVIVING SEPSIS CAMPAIGN: GUIDELINES ON THE MANAGEMENT OF CRITICALLY ILL ADULTS WITH CORONAVIRUS DISEASE 2019 (COVID-19)

COVID-19 THERAPY RECOMMENDATIONS CHART

CYTOKINE STORM

RECOMMENDATION #41	STRENGTH & QUALITY OF EVIDENCE
In mechanically ventilated adults with COVID-19 and respiratory failure (without ARDS) , we suggest against the routine use of systemic corticosteroids.	<ul style="list-style-type: none">● Weak● Low-Quality of Evidence
RECOMMENDATION #42	STRENGTH & QUALITY OF EVIDENCE
In mechanically ventilated adults with COVID-19 and ARDS , we suggest using systemic corticosteroids, over not using corticosteroids.	<ul style="list-style-type: none">● Weak● Low-Quality of Evidence
RECOMMENDATION #43	STRENGTH & QUALITY OF EVIDENCE
In mechanically ventilated patients with COVID-19 and respiratory failure , we suggest using empiric antimicrobials/antibacterial agents, over no antimicrobials.	<ul style="list-style-type: none">● Weak● Low-Quality of Evidence
RECOMMENDATION #44	STRENGTH & QUALITY OF EVIDENCE
For critically ill adults with COVID-19 who develop fever , we suggest using acetaminophen/paracetamol for temperature control, over no treatment.	<ul style="list-style-type: none">● Weak● Low-Quality of Evidence

RECOMMENDATION #45	STRENGTH & QUALITY OF EVIDENCE
In critically ill adults with COVID-19, we suggest against the routine use of standard intravenous immunoglobulins (IVIg).	<ul style="list-style-type: none"> • Weak • Very Low-Quality Evidence
RECOMMENDATION #46	STRENGTH & QUALITY OF EVIDENCE
In critically ill adults with COVID-19, we suggest against the routine use of convalescent plasma.	<ul style="list-style-type: none"> • Weak • Very Low-Quality of Evidence
RECOMMENDATION #47.1	STRENGTH & QUALITY OF EVIDENCE
In critically ill adults with COVID-19 we suggest against the routine use of lopinavir/ritonavir.	<ul style="list-style-type: none"> • Weak • Low-Quality of Evidence
RECOMMENDATION #47.2	STRENGTH & QUALITY OF EVIDENCE
There is insufficient evidence to issue a recommendation on the use of other antiviral agents in critically ill adults with COVID-19.	Insufficient
RECOMMENDATION #48	STRENGTH & QUALITY OF EVIDENCE
There is insufficient evidence to issue a recommendation on the use of recombinant rIFNs, alone or in combination with antivirals, in critically ill adults with COVID-19.	Insufficient
RECOMMENDATION #49	STRENGTH & QUALITY OF EVIDENCE
There is insufficient evidence to issue a recommendation on the use of chloroquine or hydroxychloroquine in critically ill adults with COVID-19.	Insufficient
RECOMMENDATION #50	STRENGTH & QUALITY OF EVIDENCE
There is insufficient evidence to issue a recommendation on the use of tocilizumab in critically ill adults with COVID-19.	Insufficient